1. Fremanezumab, a migraine prevention drug, may reduce both migraine frequency and depressive symptoms in adult patients with comorbid migraine and major depressive disorder.
2. The study involved 353 adult patients from 12 countries and demonstrated significant improvements in migraine days, depressive symptoms, and overall quality of life.
3. Patients receiving fremanezumab had an average of 5.1 fewer migraine days per month and a reduction in depressive symptoms.
4. Adverse events, mostly mild or moderate, were reported in 40% of fremanezumab users and 27% of placebo users.
5. The study population was predominantly female (88%) and White (97%) with a mean age of 43 years.
6. Further research is needed to fully comprehend the relationship between migraine control and mood outcomes.

Source: JAMA Neurology